New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 18, 2014
07:59 EDTOHRPOhr Pharmaceutical negative report was misleading, says Brean Capital
Brean Capital believes last week's negative report on Ohr Pharmaceuticals was misleading. The firm believes its squalamine eye drops will be effective and expects the company to enter a joint venture to further develop it trodusquemine drug for yet undisclosed new indications. Shares are Buy rated with a $21 price target.
News For OHRP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 16, 2015
08:08 EDTOHRPOhr Pharmaceutical presents new data from OHR-102 Phase II IMPACT study
Ohr Pharmaceutical presented additional positive data from the Phase 2 IMPACT study evaluating OHR-102 combination therapy for the treatment of the wet form of age-related macular degeneration, or wet-AMD. The data were presented by Dr. David S. Boyer, retina specialist at Retina-Vitreous Associates Medical Group and investigator in the study, at the annual meeting of the American Academy of Ophthalmology, or AAO, in Las Vegas. New data from the IMPACT study demonstrates that visual acuity outcomes correlate with the size and composition of lesions in the study patients. Previously, a positive benefit in terms of visual acuity outcomes was shown in patients with classic containing lesions. Detailed analyses of lesion characteristics and their predictive effect on visual acuity outcomes demonstrated that the smaller the occult CNV size, the more pronounced the combination treatment effect on visual acuity, whether or not there was a classic component present. This size effect was not observed in those patients treated with Lucentis monotherapy. The size of occult CNV, irrespective of a classic CNV component, was most important in predicting treatment success with the combination of OHR-102 plus Lucentis. In those patients with occult CNV less than 10mm2 in area, 40% of those treated with the combination of OHR-102 plus Lucentis achieved a gain of 3 or more lines of vision, compared with 26% of patients in the Lucentis monotherapy arm, a 54% additional benefit. In addition, mean gains in visual acuity compared to baseline were +11.0 letters for the OHR-102 plus Lucentis combination arm and +5.7 letters with Lucentis monotherapy, a clinically meaningful benefit of +5.3 letters. Importantly, this group of patients represents a larger proportion of the subjects enrolled in the IMPACT study than the classic containing group.
November 13, 2015
08:22 EDTOHRPAmerican Academy of Ophthalmology to hold annual meeting
AAO 2015 is being held in Las Vegas, Nevada on November 13-17 with webcasted presentations to begin on November 13 at 11:50 am. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use